Back to Browse Journals » ClinicoEconomics and Outcomes Research » Volume 1

Management strategies and cost effectiveness in the prevention of cervical cancer

Authors Smita R Prasad

Published Date June 2009 Volume 2009:1 Pages 17—23

DOI http://dx.doi.org/10.2147/CEOR.S4226

Published 5 June 2009

Smita R Prasad

University of Kentucky, College of Public Health, Lexington, KY, USA

Abstract: This paper introduces the burden of cervical cancer and the primary and secondary preventative interventions currently available, and provides an overview of the bivalent and quadrivalent human papillomavirus (HPV) vaccines. A brief account of the virology and the clinical efficacy of both is given. Examinations of the two main types of cost analyses, cost-effective and cost-benefit, as well as examples, are presented in addition to the possible impact these analyses and further economic models will have on budget and policy making decisions. In general, most cost analyses provide support for the implementation of primary prevention strategies, HPV immunization, in conjunction with cervical cancer screening programs. Vaccination against HPV, therefore, is a cost-effective cervical cancer prevention mechanism.

Keywords: cervical cancer, human papillomavirus, HPV

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells [Corrigendum]

Yu L, Wang XL, Zhu D, Ding WC, Wang LM, Zhang CL, Jiang XH, Shen H, Liao SJ, Ma D, Hu Z, Wang H

OncoTargets and Therapy 2015, 8:365-366

Published Date: 4 February 2015

Smart Grid and nanotechnologies: a solution for clean and sustainable energy

Markovic DS, Branovic I, Popovic R

Energy and Emission Control Technologies 2015, 3:1-13

Published Date: 23 January 2015

Isolated posterior uveal effusion: expanding the spectrum of the uveal effusion syndrome

Pautler SE, Browning DJ

Clinical Ophthalmology 2015, 9:43-49

Published Date: 30 December 2014

Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy

Gerald HJ Mickisch, Björn Schwander, Bernard Escudier, et al

ClinicoEconomics and Outcomes Research 2011, 3:19-27

Published Date: 25 January 2011

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

Xiaomei Peng, Haya Ascher-Svanum, Douglas Faries et al

ClinicoEconomics and Outcomes Research 2011, 3:9-14

Published Date: 11 January 2011

Inpatient charges and mental illness: Findings from the Nationwide Inpatient Sample 1999–2007

Jim E Banta, Ivorie Belk, Kedon Newton, et al

ClinicoEconomics and Outcomes Research 2010, 2:149-158

Published Date: 11 October 2010

Impact of disability on different domains of health-related quality of life in the noninstitutionalized general population

Javier Mar, Isabel Larrañaga, Arantzazu Arrospide, et al

ClinicoEconomics and Outcomes Research 2010, 2:97-103

Published Date: 14 July 2010